Lord Freyberg: To ask Her Majesty’s Government why they have decided to exhibit items from the Government Art Collection in a new London venue rather than outside the capital; and what the cost of the exhibition, including the new venue, will be.
Lord Freyberg: To ask Her Majesty’s Government what is their response to the findings of the Healthcare Quality Improvement Partnership’s National Audit of Cardiac Rhythm Management Devices April 2015 to March 2016 published on 14 February.
Lord Freyberg: To ask Her Majesty’s Government what is their response to the findings of the Healthcare Quality Improvement Partnership’s National Chronic Obstructive Pulmonary Disease Audit Programme: National supplementary report published on 1 February.
Lord Freyberg: To ask Her Majesty’s Government, with respect to chronic obstructive pulmonary disease, what was the NHS's annual clinical negligence bill for the 2016–17 financial year and what it is projected to be for the 2017–18 financial year; whether any statistical correlations between negligence payments made by NHS Trusts and care quality indicators have been examined; and if so, what are...
Lord Freyberg: To ask Her Majesty’s Government with respect to cardiac rhythm management devices, what was the NHS's annual clinical negligence bill for the 2016–17 financial year and what it is projected to be for the 2017–18 financial year; whether any statistical correlations between negligence payments made by NHS Trusts and care quality indicators have been examined; and if so, what are those...
Lord Freyberg: To ask Her Majesty’s Government how much revenue has been collected through VAT on imported works of art in each financial year since 2010–11.
Lord Freyberg: To ask Her Majesty’s Government how many centres carry out complex thoracic surgery in NHS England; what is their annual procedure volume; and when they will publish risk normalised outcome data for those centres.
Lord Freyberg: To ask Her Majesty’s Government how the proposal by Companies House to change the policy of retention of dissolved company records from 20 years to six years will affect the ability of those who have contracted mesothelioma to seek to bring claims for compensation against their former employers and companies which have dissolved before the claimants' diagnosis.
Lord Freyberg: To ask Her Majesty’s Government what discussions have taken place with the Asbestos Victims Support Groups Forum UK, the British Lung Foundation and other relevant bodies regarding the proposal by Companies House to change the policy of retention of dissolved company records from 20 years to six years.
Lord Freyberg: To ask Her Majesty’s Government when the Department for Education will publish their response to the consultation on their plans to make it compulsory for all pupils starting secondary school in 2015 to take the English Baccalaureate subjects when they reach their GCSEs in 2020.
Lord Freyberg: To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 25 July (HL1340), what assessment they have made of the relative clinical benefits of the drug lenvatinib as opposed to sorafenib.
Lord Freyberg: To ask Her Majesty’s Government on what date the Department of Health referred lenvatinib to NICE for a full technology appraisal.
Lord Freyberg: To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 25 July (HL1340), what date has been agreed by NICE for a full technology appraisal of lenvatinib.
Lord Freyberg: To ask Her Majesty’s Government when they expect lenvatinib to be available on the NHS for patients with radioiodine refractory differentiated thyroid cancer.
Lord Freyberg: To ask Her Majesty’s Government what measures they intend to put in place to ensure that patients with radioiodine refractory differentiated thyroid cancer can receive all effective clinical treatments currently available through EU authorisation.
Lord Freyberg: To ask Her Majesty’s Government how many postgraduate students in England were enrolled in two-year masters’ degree courses in (1) 2009–10, (2) 2010–11, (3) 2011–12, (4) 2012–13, (5) 2013–14, (6) 2014–15, and (7) 2015–16.
Lord Freyberg: To ask Her Majesty’s Government how many postgraduate students in England were enrolled in two-year masters’ degree courses to study (1) applied art and design, (2) art and design, (3) drama, (4) media, film or TV, (5) music, (6) dance, (7) performing arts, and (8) design and technology, in (a) 2009–10, (b) 2010–11, (c) 2011–12, (d) 2012–13, (e) 2013–14, (f) 2014–15, and (g)...
Lord Freyberg: To ask Her Majesty’s Government what discussions they have had about patients' access to rare cancer medicines that have received a marketing authorisation after the closure of the old Cancer Drugs Fund list and before the launch of the new Cancer Drugs Fund on 29 July, but that have not yet been approved by NICE.
Lord Freyberg: To ask Her Majesty’s Government whether they plan to consider providing interim funding for innovative treatments for patients with radioactive-iodine refractory differentiated thyroid cancer where there are treatments available but they are yet to be reviewed by NICE.
Lord Freyberg: To ask Her Majesty’s Government what steps they are taking to ensure that patients suffering with radioactive iodine-refractory differentiated thyroid cancer are not denied treatment due to the timeframes applied by NHS England for access to the new Cancer Drugs Fund.